Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 14/20 | 0.49 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7807640 | 0.82 | KMT2A (0.42) | ALDH1A1LMNA | |
| SCHEMBL28325008 | 0.82 | CA12 (0.57) | ACHECA12CA1CA2CA9 | |
| SCHEMBL19449057 | 0.81 | ACHE (0.47) | ACHECA12CA1CA2CA9 | |
| SCHEMBL23056273 | 0.81 | ACHE (0.45) | ACHECA12CA1CA2CA9 | |
| SCHEMBL23055921 | 0.79 | ACHE (0.44) | ACHECA12CA1CA2CA9 | |
| SCHEMBL17449239 | 0.79 | CA12 (0.48) | ACHECA12CA1CA2CA9 | |
| SCHEMBL28317648 | 0.79 | ALDH1A1 (0.55) | ACHECA12CA2CA9ALDH1A1 | |
| SCHEMBL23613234 | 0.78 | EPHX1 (0.38) | ACHECA12CA1CA2CA9 | |
| SCHEMBL15356406 | 0.78 | EPHX1 (0.34) | ACHE | |
| SCHEMBL12390787 | 0.78 | ACHE (0.46) | ACHECA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190290784-A1 | LUCIFERIN DERIVATIVES FROM BICYCLIC REACTANTS AND AMINOTHIOL DERIVATIVES AND METHODS OF USE THEREOF | UNIV CALIFORNIA (US) | 2019-09-26 | — | — | US | disclosed |
| US-10328161-B2 | Luciferin derivatives from bicyclic reactants and aminothiol derivatives and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10328161-B2 | Luciferin derivatives from bicyclic reactants and aminothiol derivatives and methods of use thereof | GFPT1, QPCT, GLB1 | ACHE 61/4885CA12 2557/4885CA1 2979/4885 |
| US-20190290784-A1 | LUCIFERIN DERIVATIVES FROM BICYCLIC REACTANTS AND AMINOTHIOL DERIVATIVES AND METHODS OF USE THEREOF | GFPT1, QPCT, GLB1 | ACHE 61/4885CA12 2557/4885CA1 2979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.